Treatment outcome of anaplastic thyroid cancer patients in Vietnam (period 2014-2022)
N.-V. Dang, N.-C. Tin, N.-D. Duc, H.T.V. Thanh Vietnam National Cancer Hospital, Hanoi, Vietnam. nguyendinhduchmuvn@gmail.com
OBJECTIVE: Anaplastic thyroid carcinoma (ATC) is an endocrine tumor with low incidence and one of the most aggressive human malignancies. The median survival is only 3-10 months, and the optimal therapeutic approach as well as prognostic factors have not been established. The aim of this study was to evaluate the long-term survival and good prognostic factors of patients with ATC.
PATIENTS AND METHODS: The retrospective study used our institution’s single-center database system. 31 patients with histopathological confirmation of anaplastic thyroid cancer from January 2014 to June 2022 were included.
RESULTS: 31 patients with ATC [11 males (35.5%), 20 females (64.5%); average age, 58.7 years] were identified, 32.3% were stage IVA, 32.3% stage IVB, and 35.4% IVC. The median overall survival (OS) of the entire cohort was 6.9 ± 1.45 months. The OS at two years was 12.1%. The female with no cervical lymph node metastasis, undergoing surgery, and tumor size < 6 cm were associated with improved OS. Patients undergoing surgery followed by chemoradiation therapy had the highest median OS (11 ± 1.83 months) and 21.8% of 2-year survival.
CONCLUSIONS: Anaplastic thyroid carcinoma is a highly malignant tumor. Patients receiving surgical resection had better OS than patients without these treatments. The combination of surgery and chemoradiation could improve OS.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
N.-V. Dang, N.-C. Tin, N.-D. Duc, H.T.V. Thanh
Treatment outcome of anaplastic thyroid cancer patients in Vietnam (period 2014-2022)
Eur Rev Med Pharmacol Sci
Year: 2024
Vol. 28 - N. 20
Pages: 4442-4450
DOI: 10.26355/eurrev_202410_36867